Resistance Surveillance in Italy: Four-Year Results from the MYSTIC Program

References

• Oppenheim BA. The changing pattern of infection in neutropenic patients. J Antimicrob Chemother 1998; 41 (Suppl. D): 7-11.
   Google Scholar
• Giwercman B, Lambert PA, Rosdahl VT, Shand H, Hoiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed beta-lactamase producing strains. J Antimicrob Chemother 1990; 26: 247–259.
   PubMed Web of Science ®Google Scholar
• Jones RN. Impact of changing pathogens and antimicro-bial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996; 100 (Suppl. 6A): 3S-12S.
   Google Scholar
• Felmingham D, Gruneberg RN. The Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45; 191-203.
   Google Scholar
• Pfaller MA, Jones RN, Doern GV, Kugler K, and the SENTRY Participants Group. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occur-rence and antimicrobial susceptibility patterns from the SEN-TRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762–1770.
   Google Scholar
• Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999. Am J Infect Contr 1999; 27: 520–532.
   PubMedGoogle Scholar
• Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial blood stream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29: 239–244.
   PubMed Web of Science ®Google Scholar
• Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis 1997; 24 (Suppl.1): S157-168.
   Google Scholar
• Goettsch W, Bronzwaer SL, de Neeling AJ, et al. Standardization and quality assurance for antimicrobial surveil-lance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). Clin Microbiol Infect 2000; 6: 59–63.
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2. Clin Infect Dis 1999; 29: 245–252.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The mystic (Meropenem Yearly Susceptibility Test Information Collection) programme. Intern J Antimicrob Agents 1999; 13: 117–125.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fourth Edition: Approved Standard M7-A4. 1996; NCCLS, Villanova PA.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. M100-S11. 2000; NCCLs, Wayne, PA.
   Google Scholar
• Jones RN, Barry AL, Thornsberry C. In-vitro studies of meropenem. J Antimicrob Chemother 1989; 24 (Suppl. A): 9-29.
   Google Scholar
• Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1997; 28: 157–163.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Edwards JR. A compilation of studies assessing the in vitro activity of meropenem and comparators in 84 laboratories throughout Europe. Clin Microbiol Infect 1997; 3 (Suppl. 4): 32-50.
   Google Scholar
• Garcia-Rodriguez J-A, Jones RN, and The MYSTIC Programme Study Group. Antimicrobial resistance in Gram-negative isolates from European Intensive Care Units: data from the meropenem yearly susceptibility test information col-lection (MYSTIC) programme. J Chemother 2002; 14: 25–32.
   Google Scholar
• Sanders WE. Jr, Sanders CC. Enterobacter spp.: a pathogen poised to flourish at the turn of the century. Clin Microbiol Rev 1997; 10: 220–241.
   Google Scholar
• Bonfiglio G, Carciotto V, Russo G, et al. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1998; 41: 307–310.
   PubMed Web of Science ®Google Scholar
• Buscher KH, Cullmann W, Dick W, Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother 1987; 31: 703–708.
   PubMed Web of Science ®Google Scholar
• Li XZ, Ma D, Livermore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance. Antimicrob Agents Chemother 1994; 38: 1742–1752.
   PubMed Web of Science ®Google Scholar
• Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. Appearance of IMP-1 metallo-beta-lactamase in Europe. Lancet 1999; 353: 899–900.
   PubMed Web of Science ®Google Scholar
• Fung-Tomc JC, Huczko E, Banville J, et al. Structure-activity relationships of carbapenems that determine their dependence on porin protein D2 for activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995; 39: 394–399.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Jones RN, for the MYSTIC Study Group (Americas). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000; 46 (Topic T2): 25-37.
   Google Scholar
• Goossens H, for the MYSTIC Study group (European centres only). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Europe: comparison of antibiotic susceptibilities between countries and centre types. J Antimicrob Chemother 2000; 46 (Topic T2): 39-52.
   Google Scholar
• Hesiby N, Ciofu O, Jensen T, Pressler T, Johansen HK, Koch C. Use of carbapenems and other antibiotics for pul-monary infections in patients with cystic fibrosis. Ped Infect Dis J 1996; 15: 738–743.
   PubMed Web of Science ®Google Scholar
• Ciofu O, Jensen T, Pressler T, Johansen HK, Koch C, Hesiby N. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin Microbiol Infect 1996; 2: 91–98.
   PubMedGoogle Scholar
• Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996; 40: 1108–1115.
   PubMed Web of Science ®Google Scholar
• Colardyn F, Faulkener KL and The Meropenem Serious Infection Study Group. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infec-tions in hospitalised patients. J Antimicrob Chemother 1996; 38: 523–537.
   Google Scholar